Literature DB >> 16255752

A Latin American registry of implantable cardioverter defibrillators: the ICD-LABOR study.

Sergio Dubner1, Elina Valero, Ricardo Pesce, Jorge González Zuelgaray, José C Pachon Mateos, Silas Galvao Filho, Walter Reyes, Raúl Garillo.   

Abstract

OBJECTIVE: Despite the progress that has been reached in emergency medical systems and resuscitation, sudden cardiac death (SCD) continues to be the major cause of the death, and remains a significant public health problem. In this publication we are reporting our Latin American experience in the secondary prevention of SCD, by means of an ongoing registry involving seven Latin American countries and 770 patients.
METHODS: Every individual within the present registry to date has presented with antecedents of aborted sudden death or cardiac arrest due to ventricular tachycardia or ventricular fibrillation. Patients included have fulfilled the Class I indication for implantable cardioverter defibrillator (ICD) and they were implanted with a Biotronik ICD (all models). The study was not sponsored by Biotronik, nor did they have access to the data. A specific protocol was designed for implantation and follow-up of patients. The database was completely registered through the Internet and a personal password was assigned to each group of investigators. The primary end point was death from all causes. Secondary end points were SCD and death due to congestive heart failure (CHF).
RESULTS: The etiology of cardiac disease was found to be predominantly coronary artery disease (CAD) 39.7% (306 patients), followed by Chagas disease (ChD), 26.1% (201 patients), and idiopathic dilated cardiomyopathy (DCM), 17% (131 patients). Any remaining pathologies were included as miscellaneous 13.2% (101 patients). In 31 patients (4%) the etiology was unknown. The age did not differ within the principal pathologies, but was significantly older than the miscellaneous group (62.0 +/- 11.3 years vs 48.2 +/- 18.9 years, P < 0.0001). The follow-up period was 27 +/- 25 months (1-113 months) for the whole group. The mortality in functional classes I-II was significantly lower than mortality for functional classes III-IV (relative risk 1.46, CI 95%, P < 0.0001). Mean left ventricular ejection fraction (LVEF) for the whole group was 37.7 +/- 14.3%. Male LVEF was 36.1 +/- 14.1% and female LVEF was 42.2 +/- 13.8% P < 0.0001. During the follow-up period, 130 deaths were reported (global mortality 16.9 +/- 9.7%), out of which 84 (64.6%) were attributed to cardiac causes (10.9 +/- 5.1% of the total population). The annual adjusted cardiac mortality was 5.2 +/- 1.72% (range 3.5-7.0%). Among cardiac deaths the most common cause was progressive heart failure, 48 patients (57%) including 3 patients with pulmonary embolism. The second main cause of cardiac death was SCD, 36 patients (43%), including 4 patients with electrical storm and 3 patients with electromechanical dissociation after multiple shock therapy treatments.
CONCLUSIONS: Despite the differences in terms of pathologies between the ICD-LABOR (Latin American bioelectronic ongoing registry) and randomized ICD trials, a parallel evolution in all cause mortality and cardiac mortality was observed. Independent risk factors for mortality included age >70 years, male gender, NYHA III/IV, and ejection fraction <0.30. The etiology of heart disease (Chagas vs Coronary Disease) was not found to be a risk factor.

Entities:  

Mesh:

Year:  2005        PMID: 16255752      PMCID: PMC6932394          DOI: 10.1111/j.1542-474X.2005.00060.x

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  19 in total

Review 1.  Implantable cardioverter defibrillator therapy: the sickest patients benefit the most.

Authors:  A J Moss
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

Review 2.  Routine arrhythmia inductions for ICD follow-up: are they obsolete?

Authors:  M Glikson; P Friedman
Journal:  Pacing Clin Electrophysiol       Date:  2001-06       Impact factor: 1.976

3.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

4.  Clinical characteristics of unexplained sudden cardiac death in Korea.

Authors:  J G Cho; H W Park; J Y Rhew; S R Lee; W K Chung; O Y Park; W Kim; K H Kim; K T Kang; S H Lee; N H Kim; J C Park; Y K Ahn; M H Jeong; J C Park; J C Kang
Journal:  Jpn Circ J       Date:  2001-01

Review 5.  Progressive depolarization: a unified hypothesis for defibrillation and fibrillation induction by shocks.

Authors:  S M Dillon; K F Kwaku
Journal:  J Cardiovasc Electrophysiol       Date:  1998-05

Review 6.  Sudden death prevention in patients with advanced ventricular dysfunction.

Authors:  W G Stevenson; L W Stevenson; H R Middlekauff; L A Saxon
Journal:  Circulation       Date:  1993-12       Impact factor: 29.690

7.  Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators.

Authors:  M J Domanski; S Sakseena; A E Epstein; A P Hallstrom; M A Brodsky; S Kim; S Lancaster; E Schron
Journal:  J Am Coll Cardiol       Date:  1999-10       Impact factor: 24.094

Review 8.  Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials.

Authors:  Justin A Ezekowitz; Paul W Armstrong; Finlay A McAlister
Journal:  Ann Intern Med       Date:  2003-03-18       Impact factor: 25.391

9.  Distinct clinical features in the recipients of the implantable cardioverter defibrillator in Taiwan: a multicenter registry study.

Authors:  Chia-Ti Tsai; Shoei K Stephen Huang; Jiunn-Lee Lin; Ling-Ping Lai
Journal:  Pacing Clin Electrophysiol       Date:  2003-11       Impact factor: 1.976

10.  Gender differences in device therapy for malignant ventricular arrhythmias.

Authors:  H L Horton; R A Marinchak; S J Rials; P R Kowey
Journal:  Arch Intern Med       Date:  1995-11-27
View more
  3 in total

1.  Seven years of use of implantable cardioverter-defibrillator therapies: a nationwide population-based assessment of their effectiveness in real clinical settings.

Authors:  Arn Migowski; Antonio Luiz Ribeiro; Marilia Sá Carvalho; Vitor Manuel Pereira Azevedo; Rogério Brant Martins Chaves; Lucas de Aquino Hashimoto; Carolina de Aquino Xavier; Regina Maria de Aquino Xavier
Journal:  BMC Cardiovasc Disord       Date:  2015-03-13       Impact factor: 2.298

2.  Clinical Course After Cardioverter-Defibrillator Implantation: Chagasic Versus Ischemic Patients.

Authors:  Francisca Tatiana Moreira Pereira; Eduardo Arrais Rocha; Marcelo de Paula Martins Monteiro; Neiberg de Alcantara Lima; Carlos Roberto Martins Rodrigues Sobrinho; Roberto da Justa Pires Neto
Journal:  Arq Bras Cardiol       Date:  2016-07-11       Impact factor: 2.000

3.  Long-term follow-up of patients with chronic chagas disease and implantable cardioverter-defibrillator.

Authors:  Francisca Tatiana Moreira Pereira; Eduardo Arrais Rocha; Marcelo de Paula Martins Monteiro; Almino Cavalcante Rocha Neto; Elisabeth de Francesco Daher; Carlos Roberto Martins Rodrigues Sobrinho; Roberto da Justa Pires Neto
Journal:  Pacing Clin Electrophysiol       Date:  2014-01-27       Impact factor: 1.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.